These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2472582)

  • 61. [Intravenous infusion of L-dopa: current prospective therapies].
    Peppe A; De Angelis D; Tolli VS; Rizzo PA; Scoppetta C
    Riv Neurol; 1991; 61(5):197-200. PubMed ID: 1808680
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The pharmacology of foot dystonia in parkinsonism.
    Poewe WH; Lees AJ
    Clin Neuropharmacol; 1987; 10(1):47-56. PubMed ID: 3545460
    [No Abstract]   [Full Text] [Related]  

  • 64. Continuous duodenal levodopa infusion in a patient with Crohn's disease and small bowel surgery - Case report.
    Tomic S; Skelac D; Mick D; Segec I; Resan B; Soldo SB
    J Neurol Sci; 2015 Nov; 358(1-2):525-6. PubMed ID: 26443281
    [No Abstract]   [Full Text] [Related]  

  • 65. [Dystonia sensitive to levodopa].
    Ochoa JJ; Bescansa E; Sánchez López F; Cañadillas F; Viñals M
    Neurologia; 1992 Apr; 7(4):73-6. PubMed ID: 1627344
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
    Schuh LA; Bennett JP
    Neurology; 1993 Aug; 43(8):1545-50. PubMed ID: 8351009
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family.
    Nygaard TG; Trugman JM; de Yebenes JG; Fahn S
    Neurology; 1990 Jan; 40(1):66-9. PubMed ID: 2296384
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Parkinsonism following dystonia in three patients.
    Katchen M; Duvoisin RC
    Mov Disord; 1986; 1(2):151-7. PubMed ID: 3504239
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The long-term response to levodopa in dopa-responsive dystonia.
    Hwang WJ; Calne DB; Tsui JK; de la Fuente-Fernández R
    Parkinsonism Relat Disord; 2001 Sep; 8(1):1-5. PubMed ID: 11472874
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology.
    Poewe W; Lees AJ; Steiger D; Stern GM
    Adv Neurol; 1987; 45():357-60. PubMed ID: 3825711
    [No Abstract]   [Full Text] [Related]  

  • 72. Effects of Levodopa on Vowel Articulation in Patients with Parkinson's Disease.
    Okada Y; Murata M; Toda T
    Kobe J Med Sci; 2015 Apr; 61(5):E144-54. PubMed ID: 27363398
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Severe ataxic polyneuropathy associated with chronic levodopa use in Parkinson's disease.
    Kimber T; Blumbergs P; Thompson P
    Parkinsonism Relat Disord; 2013 Sep; 19(9):847-9. PubMed ID: 23746939
    [No Abstract]   [Full Text] [Related]  

  • 74. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.
    Syed N; Murphy J; Zimmerman T; Mark MH; Sage JI
    Mov Disord; 1998 Mar; 13(2):336-8. PubMed ID: 9539350
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Spontaneous pallidal neuronal activity in human dystonia: comparison with Parkinson's disease and normal macaque.
    Starr PA; Rau GM; Davis V; Marks WJ; Ostrem JL; Simmons D; Lindsey N; Turner RS
    J Neurophysiol; 2005 Jun; 93(6):3165-76. PubMed ID: 15703229
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Levodopa for Parkinson's disease.
    Devos D; Moreau C; Destée A
    N Engl J Med; 2009 Feb; 360(9):935-6; author reply 936. PubMed ID: 19246370
    [No Abstract]   [Full Text] [Related]  

  • 77. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
    Klostermann F; Bojarski C; Marzinzik F; Maier A; Schindlbeck KA; Ehlen F
    Mov Disord; 2017 Feb; 32(2):300-301. PubMed ID: 27859611
    [No Abstract]   [Full Text] [Related]  

  • 80. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
    Baronti F; Ruggieri S; Mouradian MM; Bonamartini A; Bocciarelli P; De Pandis MF; Chase TN; Agnoli A
    Riv Neurol; 1991; 61(6):210-4. PubMed ID: 1813972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.